

PRESSRELEASE

FE-MININ Study Progressing on Schedule – Important Milestone Ahead of Upcoming Patent Application

London, 23 July 2026 – Bio Vitos Ltd today announced that the clinical FE-MININ Study is progressing according to plan and has now entered its final phase. All 80 participants are expected to have completed their blood sampling by 24 July 2026, marking an important milestone in the Company's clinical development program.

Following the completion of the clinical phase, the Company will continue with data quality assurance, collection, verification, and the final compilation of all study data. This process is expected to be completed during September 2026, after which the final scientific study report will be prepared.

Bio Vitos aims to present the results of the FE-MININ Study during September 2026. The findings are expected to provide important scientific evidence supporting the Company's continued development and will form the basis of a forthcoming patent application intended to strengthen and expand the Company's existing patent protection relating to the treatment of heart defects.

The FE-MININ Study is a key component of Bio Vitos' research program and long-term strategy to develop scientifically validated therapies with international commercial potential. The clinical results are expected to further strengthen the Company's intellectual property portfolio and support future global commercialization opportunities.



Cato Crogh, Chairman of Bio Vitos Ltd, commented:

"We are delighted that the FE-MININ Study continues to progress according to our planned timeline. Completing the clinical phase represents an important milestone for Bio Vitos. Over the coming weeks, our focus will be on data quality assurance and analysis, with the objective of presenting the study results as early as September. We believe these results will provide a strong scientific foundation for our upcoming patent application and further strengthen Bio Vitos' scientific and commercial position as we continue our international expansion."

About Bio Vitos Ltd

Bio Vitos Ltd is an international life science company focused on the development of innovative therapies and clinically validated products addressing significant unmet medical needs. Through scientific research, clinical studies, and international partnerships, the Company is developing new treatment solutions with the objective of creating long-term value for patients, healthcare providers, and shareholders through global commercialization.